Glenmark Pharma Introduces Novel FDC for Diabetic Patients
April 26, 2022 11:24Glenmark Pharmaceuticals has announced their newest fixed-dose combination (FDC) Zita Plus Pio, which will help patients with uncontrolled Type 2 diabetes. The FDC, containing Teneligliptin, with Pioglitazone, is a first-of-its-kind dose and help reduce insulin resistance by having better control over glycemic index among adults. Glenmark has claimed that it is the first company to have […]







